Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Cardiovasc Ther. 2017 Oct;35(5):10.1111/1755-5922.12281. doi: 10.1111/1755-5922.12281

Figure 3. Kaplan-Meier survival analysis after propensity score matching for PAH patients who received and not received warfarin.

Figure 3

Patients at risk for each period are shown at the bottom of the figures. Panel A includes patients after propensity score matching, panel B comprises patients in whom warfarin was given through the study and panel C omits individuals that prematurely dropped out of the study.